{"id":"placebo-to-indacaterol","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1095777","moleculeType":"Small molecule","molecularWeight":"392.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used in randomized controlled trials to establish the baseline effect of disease natural history, standard care, and patient expectation. It allows researchers to isolate the true therapeutic effect of the active drug (indacaterol in this case) by comparison. Placebo responses can be substantial due to psychological and physiological factors.","oneSentence":"Placebo has no active pharmacological mechanism and serves as a control comparator in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:26.693Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Used as control arm in clinical trials comparing indacaterol efficacy and safety"}]},"trialDetails":[{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Asthma","enrollment":304},{"nctId":"NCT06035393","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-01-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":82},{"nctId":"NCT06841640","phase":"PHASE1, PHASE2","title":"Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD","status":"COMPLETED","sponsor":"AeroRx Therapeutics Inc.","startDate":"2025-01-15","conditions":"COPD","enrollment":24},{"nctId":"NCT06067100","phase":"NA","title":"U-LABA/ICS Effects on Exercise Performance, Indacaterol","status":"RECRUITING","sponsor":"Morten Hostrup, PhD","startDate":"2024-01-15","conditions":"Exercise Performance","enrollment":30},{"nctId":"NCT06619210","phase":"PHASE2","title":"A Trial to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2022-01-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":102},{"nctId":"NCT02579850","phase":"PHASE3","title":"2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05-29","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1532},{"nctId":"NCT02634983","phase":"PHASE4","title":"QVA Mechanistic Efficacy Study (Receptor Effects, Etc)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":31},{"nctId":"NCT03257995","phase":"PHASE2","title":"Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-05","conditions":"Asthma","enrollment":54},{"nctId":"NCT00624702","phase":"PHASE1","title":"Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Asthma","enrollment":98},{"nctId":"NCT02598505","phase":"PHASE3","title":"Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation","status":"COMPLETED","sponsor":"Centro Cardiologico Monzino","startDate":"2015-09","conditions":"Heart Failure","enrollment":44},{"nctId":"NCT02567214","phase":"PHASE4","title":"Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Laval University","startDate":"2016-06","conditions":"COPD","enrollment":50},{"nctId":"NCT02442206","phase":"PHASE4","title":"Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-18","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":62},{"nctId":"NCT02573155","phase":"PHASE1","title":"Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10","conditions":"Asthma (Part 1), COPD (Part 2)","enrollment":134},{"nctId":"NCT02233543","phase":"PHASE4","title":"A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":38},{"nctId":"NCT00570778","phase":"PHASE2","title":"Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":154},{"nctId":"NCT02487498","phase":"PHASE3","title":"Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-27","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":355},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":967},{"nctId":"NCT02487446","phase":"PHASE3","title":"Efficacy and Safety Study of QVA149 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":357},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT01715311","phase":"PHASE4","title":"Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT01845623","phase":"PHASE2","title":"A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08","conditions":"Asthma","enrollment":""},{"nctId":"NCT00403637","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Asthma","enrollment":45},{"nctId":"NCT01610037","phase":"PHASE3","title":"Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1215},{"nctId":"NCT01996319","phase":"PHASE3","title":"Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":194},{"nctId":"NCT01682863","phase":"PHASE3","title":"A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":614},{"nctId":"NCT01727141","phase":"PHASE3","title":"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1042},{"nctId":"NCT01697696","phase":"PHASE3","title":"Long Term Safety Study of NVA237 vs QAB149 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":511},{"nctId":"NCT00999908","phase":"PHASE3","title":"Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":54},{"nctId":"NCT01012765","phase":"PHASE3","title":"Effect of Indacaterol on Inspiratory Capacity (IC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":173},{"nctId":"NCT01699685","phase":"PHASE3","title":"Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease: COPD","enrollment":79},{"nctId":"NCT01778062","phase":"PHASE3","title":"Indacaterol EfectIveness In COPD Patients With Tuberculosis History","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02","conditions":"Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis","enrollment":136},{"nctId":"NCT01712516","phase":"PHASE3","title":"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1001},{"nctId":"NCT01959412","phase":"PHASE2","title":"Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11","conditions":"Asthma","enrollment":91},{"nctId":"NCT01484197","phase":"PHASE2","title":"A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Asthma","enrollment":36},{"nctId":"NCT01709903","phase":"PHASE3","title":"A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":744},{"nctId":"NCT01609478","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Asthma","enrollment":335},{"nctId":"NCT01604278","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":449},{"nctId":"NCT01377051","phase":"PHASE4","title":"Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea","status":"COMPLETED","sponsor":"University of Milan","startDate":"2011-05","conditions":"COPD, Lung Diseases, Dyspnea","enrollment":60},{"nctId":"NCT01574651","phase":"PHASE3","title":"The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":934},{"nctId":"NCT01529632","phase":"PHASE3","title":"Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":193},{"nctId":"NCT01490125","phase":"PHASE3","title":"The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":247},{"nctId":"NCT01202188","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2144},{"nctId":"NCT00927901","phase":"PHASE2","title":"Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06","conditions":"Asthma","enrollment":30},{"nctId":"NCT01315249","phase":"PHASE3","title":"QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":523},{"nctId":"NCT01543828","phase":"PHASE4","title":"Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01","conditions":"COPD","enrollment":40},{"nctId":"NCT00556673","phase":"PHASE2","title":"Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"Asthma","enrollment":31},{"nctId":"NCT00605306","phase":"PHASE2","title":"Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Asthma","enrollment":28},{"nctId":"NCT00557440","phase":"PHASE2","title":"Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Asthma","enrollment":37},{"nctId":"NCT01294787","phase":"PHASE3","title":"Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02","conditions":"COPD","enrollment":85},{"nctId":"NCT01120717","phase":"PHASE3","title":"A Study to Assess the Long-term Safety of QVA149","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":339},{"nctId":"NCT00545272","phase":"PHASE2","title":"A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-10","conditions":"Asthma","enrollment":392},{"nctId":"NCT00557466","phase":"PHASE2","title":"A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10","conditions":"COPD","enrollment":568},{"nctId":"NCT00558285","phase":"PHASE2","title":"Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":257},{"nctId":"NCT01498081","phase":"PHASE2","title":"A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-03","conditions":"COPD","enrollment":39},{"nctId":"NCT00531050","phase":"PHASE2","title":"Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":27},{"nctId":"NCT00396604","phase":"PHASE2, PHASE3","title":"Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":51},{"nctId":"NCT00669617","phase":"PHASE3","title":"Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":89},{"nctId":"NCT00636961","phase":"PHASE2","title":"An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":27},{"nctId":"NCT00529529","phase":"PHASE3","title":"Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-09","conditions":"Asthma","enrollment":805},{"nctId":"NCT01012739","phase":"PHASE2","title":"Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-10","conditions":"Asthma","enrollment":35},{"nctId":"NCT00877383","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1142},{"nctId":"NCT00677807","phase":"PHASE3","title":"Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-05","conditions":"COPD","enrollment":415},{"nctId":"NCT01068600","phase":"PHASE3","title":"Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":318},{"nctId":"NCT01072448","phase":"PHASE3","title":"12-week Efficacy of Indacaterol","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":323},{"nctId":"NCT00900731","phase":"PHASE3","title":"A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1598},{"nctId":"NCT01079130","phase":"PHASE3","title":"Efficacy and Safety of Different Doses of Indacaterol","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-02","conditions":"Asthma","enrollment":511},{"nctId":"NCT01089127","phase":"PHASE3","title":"Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":552},{"nctId":"NCT00846586","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1134},{"nctId":"NCT00567996","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1002},{"nctId":"NCT00393458","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1732},{"nctId":"NCT00821093","phase":"PHASE3","title":"Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1123},{"nctId":"NCT00463567","phase":"PHASE2, PHASE3","title":"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":2059},{"nctId":"NCT00624286","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":416},{"nctId":"NCT00622635","phase":"PHASE3","title":"A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":68},{"nctId":"NCT00792805","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":563},{"nctId":"NCT00403754","phase":"PHASE2","title":"Dose Ranging Study for Indacaterol in Japanese Asthma Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Asthma","enrollment":41},{"nctId":"NCT00794157","phase":"PHASE3","title":"Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":347},{"nctId":"NCT00615459","phase":"PHASE3","title":"A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":169},{"nctId":"NCT00620022","phase":"PHASE3","title":"The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":90},{"nctId":"NCT01156844","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03","conditions":"Persistent Asthma","enrollment":191},{"nctId":"NCT00403845","phase":"PHASE2","title":"Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":50},{"nctId":"NCT00615030","phase":"PHASE3","title":"Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":96},{"nctId":"NCT01263808","phase":"PHASE1","title":"Cardiac Safety of Indacaterol","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Healthy Volunteers, Chronic Obstructive Pulmonary Disease","enrollment":404}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":147,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo to indacaterol","genericName":"Placebo to indacaterol","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo has no active pharmacological mechanism and serves as a control comparator in clinical trials. Used for Used as control arm in clinical trials comparing indacaterol efficacy and safety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}